Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

OMS906 is being tested in a Phase 2 rare-kidney-disease setting with two related but distinct populations, C3G and ICGN. That helps recruitment, but it also introduces biological and clinical heterogeneity that can dilute any efficacy signal in what is likely a small mid-stage study. The written primary endpoint is effectively safety/adverse events over 48 weeks, which lowers the bar for avoiding a clear failure, but a market judgment of “positive” usually still needs convincing preliminary efficacy, and this protocol frames efficacy as preliminary rather than as a hard primary outcome. The long treatment period and IV dosing add operational burden. Most importantly, the trial is still listed as recruiting even though the estimated primary completion date has already passed, which raises enrollment, timing, data-cut, and disclosure-risk concerns. With no prior efficacy evidence included in the trial fields to offset those issues, the odds of an ultimately positive readout look below even.

This is a small (~20 patient), open-label, uncontrolled Phase 2 trial with a primary safety endpoint (AE count over 48 weeks). Zaltenibart has demonstrated a clean safety profile across multiple PNH trials with no safety signals of concern, making the safety endpoint low-risk. The alternative pathway's role in C3G has been clinically validated by other AP inhibitors (iptacopan, danicopan) that reported positive Phase 3 C3G results. Novo Nordisk's $2.1B deal (closed Nov 2025) for global zaltenibart rights signals strong conviction in the asset. However, key risks include: the trial is 91 days past estimated primary completion yet still listed as Recruiting, suggesting enrollment delays possibly related to a prior protocol amendment. No C3G-specific efficacy data have been disclosed. C3G pathophysiology differs from PNH, and preliminary efficacy signals may be harder to demonstrate in ~20 patients with a heterogeneous renal disease. The definition of 'positive' is ambiguous—safety alone likely clears, but a truly positive readout requires encouraging efficacy signals too.

This is a Phase 2 trial for OMS906 in C3 Glomerulopathy and ICGN, rare kidney diseases. Phase 2 trials historically have ~30-40% success rates for progressing to Phase 3. The primary endpoint focuses on safety over 48 weeks with preliminary efficacy, which is a lower bar than a definitive efficacy endpoint. No prior human data or comparative benchmarks are provided in the summary. The trial is recruiting but past its estimated primary completion date by 91 days, suggesting possible delays. Given the rare disease indication, small patient populations, and early-stage safety-focused design, the intrinsic probability of positive results is modestly below even odds. The binary call is NO as the probability falls below 0.5.

This is a Phase 2 safety and preliminary efficacy study for OMS906 in rare kidney diseases (C3G/ICGN). The primary endpoint is safety (number of participants with Adverse Events), not a stringent efficacy measure, which increases the likelihood of a 'positive' readout on that basis. However, C3G is a challenging disease with high unmet need, and prior data for complement inhibitors in this space has been mixed. The sponsor, Omeros, has experience in complement therapeutics. While the safety-focused design lowers the bar, the inherent difficulty of the indication and the preliminary nature of the efficacy signal introduce significant uncertainty. The trial is still recruiting, and no interim data is referenced. Overall, the probability of a positive outcome is below even odds.

Phase 2 single-arm (likely) safety/PK/PD/efficacy study of OMS906 (MASP-3 inhibitor) in C3G/ICGN, rare alternative complement pathway diseases ideally matched to mechanism. Primary endpoint: AE incidence over 48 weeks, descriptive and high bar to fail (absent Phase 1 signals, presumed clean). Patient population enriched, small N (~20-30), boosts signal-to-noise for secondaries like proteinuria/eGFR stabilization. Endpoint quality solid for safety; 'positive results' driven by preliminary efficacy signals + favorable PD (C3 blockade). No prior efficacy data in fields, but sponsor Omeros' complement platform (OMS721) credible. Operational: recruiting despite -91 days to primary completion indicates delays, but topline imminent. Disclosure risk low for biotech readout. Net: clean safety probable (85%), efficacy signal moderate (60%), ~52% YES.

This Phase 2 trial for OMS906 in C3G and ICGN patients presents moderate execution and efficacy risks. The primary completion date passed 91 days ago, yet the status remains 'Recruiting', signaling significant enrollment delays or operational issues that often lead to underpowered analyses. The primary endpoint is a composite of safety (AE count) and tolerability over 48 weeks, which is a low bar for 'positive' results compared to hard efficacy endpoints. While safety data may be acceptable, preliminary efficacy signals in rare glomerular diseases are historically volatile. Omeros has faced past clinical setbacks, adding sponsor risk. Given the missed timeline and low-bar endpoint, the probability of a clearly positive readout is below 50%, as delayed rare-disease trials often yield mixed or inconclusive data.

OMS906 is a Phase 2 trial in rare renal diseases C3G/ICGN with only 48-week safety/PD endpoints, not hard efficacy outcomes like eGFR slope or proteinuria reduction. The primary endpoint is adverse events count—a low bar that doesn't guarantee clinical benefit. Omeros has struggled with commercial execution historically. The trial completed enrollment in January 2026 (91 days past primary completion), suggesting slow recruitment in rare diseases. No interim data has been disclosed, which is concerning given the competitive landscape with Apellis's pegcetacoplan already approved in C3G. Small sample size and biomarker-focused endpoints create high variance. Negative prior: Omeros's OMS721 failed in IgA nephropathy. The 45% intrinsic probability reflects modest mechanism rationale (MASP-2 inhibition) offset by weak endpoint design, execution delays, and sponsor track record.

The Phase 2 trial (NCT06209736) evaluates the MASP-3 inhibitor OMS906 (zaltenibart) in C3G/ICGN. The primary endpoint is safety-focused (adverse events over 48 weeks) in a small open-label cohort. OMS906 has already demonstrated a strong safety and efficacy profile in a Phase 2 PNH trial, validating the mechanism. Furthermore, in late 2025, Novo Nordisk acquired global rights to OMS906 for $240M upfront, with plans to advance it into Phase 3 for both PNH and C3G. This major acquisition underscores strong external validation of the asset's clinical profile and safety. Since the primary endpoint is safety and the drug has been well tolerated to date, the trial is highly likely to meet its endpoint without major safety signals. Additionally, preliminary efficacy on proteinuria is likely to be supportive given the validated MASP-3 mechanism. Therefore, a positive result announcement is highly probable.

The trial is in Phase 2, focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3G and ICGN. The study's primary endpoint involves assessing adverse events and preliminary efficacy over 48 weeks. Given that the trial is recruiting and has not yet reached its primary completion date, there's a reasonable expectation of positive results if the treatment shows promising safety and efficacy data. The indication targets a niche but severe condition, suggesting potential for a positive outcome if OMS906 demonstrates significant therapeutic effect.